VCI Global's Fintech Arm Advances Toward Full Digital Lending Rollout with Regulatory Approval, Targeting Two-Minute Loan Disbursements
License from KPKT Empowers Credilab to Deliver AI-Powered Microloans and SME Financing Nationwide – Paperless, Instant, and Branchless
KUALA LUMPUR, Malaysia, May 15, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) ('VCI Global') today announced that its fintech subsidiary, Credilab Sdn Bhd ('Credilab' or the 'Company') has secured a conditional approval for a digital moneylending license from Malaysia's Ministry of Local Government Development ('KPKT'). This regulatory green light marks a significant milestone in the company's mission to democratize access to fast, AI-driven financing across Southeast Asia.
Credilab is spearheading VCI Global's fintech expansion strategy by delivering same-day loans with near-zero non-performing loan (NPL) rates. Its proprietary decision-making engine processes real-time behavioral, transactional, and alternative credit data to score, approve, and disburse loans with exceptional accuracy and speed. With this license, Credilab is authorized to provide fully automated, end-to-end digital loans in Malaysia, including microloans and financing for small and medium-sized enterprises (SMEs), with approvals and disbursements completed in as fast as two minutes.
The license also enables VCI Global's fintech platform to operate without the need for physical branches, allowing for nationwide scalability with minimal overhead. Through a fully paperless onboarding process, AI-driven credit scoring, and instant Know Your Customer (KYC) verification, borrowers can now access capital in real time using just a smartphone.
This milestone comes on the heels of VCI Global's recently announced 155% year-on-year revenue growth in 2024 across its technology and fintech segments. The Company has also attracted strategic capital investment, including a US$1 million injection from a Dubai-based institutional investor, aimed at accelerating the development and deployment of its digital lending infrastructure.
'This license is more than regulatory approval; it's validation of the technology and vision behind Credilab. We've engineered a platform that can assess, approve, and fund loans in under two minutes, using AI and real-time data. This speed, accuracy, and scalability allow us to serve both consumers and SMEs with unprecedented efficiency,' said Henry Chai, Executive Director of Credilab and Group Chief Technology Officer of VCI Global.
According to Astute Analytica, Malaysia's microfinancing market is projected to reach US$11.68 billion by 2032, growing at a compound annual growth rate (CAGR) of 17.5% between 2024 and 2032. This growth is fueled by the region's expanding middle class, rising disposable incomes, and increasing demand for accessible, fast, and affordable credit solutions. In parallel, favorable fiscal policies and government support for fintech innovation, including progressive regulations such as Malaysia's digital lending framework, are creating a fertile environment for sector growth.
These dynamics presents a strong opportunity for Credilab to scale its AI-powered digital lending platform and solidify its position within Malaysia's and the region's broader fintech ecosystem. By offering instant, secure and inclusive financial solutions, Credilab is well-positioned to meet the credit needs of underserved consumers and SMEs, driving financial inclusion and enhancing economic resilience.
'Credilab's digital lending license marks a major inflection point in VCI Global's fintech growth journey, it unlocks true fintech velocity. This milestone reinforces our commitment to building AI-first financial infrastructure that meets the evolving credit needs of the region. With this approval, we're not just accelerating loan delivery; we're advancing financial inclusion and opening new pathways for scalable, technology-driven impact in Malaysia,' said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.
About Credilab Sdn Bhd
Credilab is a proprietary fintech platform designed to streamline the digital lending process, from online applications and credit scoring to Know Your Customer (KYC) verification and disbursement. It offers customized financial analytics, strengthens regulatory compliance, and ensures secure payment processing.
Focused on financial inclusion, Credilab provides accessible micro-financing solutions to underserved individuals, bridging the credit gap with advanced technology and user-centric design.
Key features of Credilab include:
Instant Cash Loans with minimal documentation
Short Processing Times for fast disbursements
Flexible and Convenient Repayment Options
For more information, please log on to https://www.credilab.my/.
About VCI Global Limited
VCI Global is a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy. With a strong presence in Asia, Europe, and the United States, VCI Global is committed to driving technological innovation, sustainable growth, and financial excellence across multiple industries.
For more information on the Company, please log on to https://v-capital.co/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission ('SEC'). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.
CONTACT INFORMATION:
For media queries, please contact:
VCI GLOBAL LIMITEDenquiries@v-capital.co
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Asia-Pacific Pediatric Interventional Cardiology Industry Report 2025-2033: Insights Into Markets, Shares, Companies, Trends, Growth Opportunities and More
Driving factors include rising congenital heart defect cases, healthcare advancements, governmental support, and demographic trends in China and India Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pediatric Interventional Cardiology Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to reach US$ 1.52 billion by 2033 from US$ 829.09 million in 2024, with a CAGR of 7.01% from 2025 to 2033. Increased cases of congenital heart defects, improved healthcare infrastructure, increased public awareness, technological innovations, encouraging governmental support, and increasing child populations - especially in developing countries such as China and India - are all contributing to the Asia-Pacific pediatric interventional cardiology market. The specialty branch of pediatric interventional cardiology is committed to minimally invasive diagnosis and treatment of cardiac ailments in neonates, children, and adolescents. Interventional cardiologists perform procedures such as fixing congenital heart defects, opening narrowed valves or arteries, and closing septal defects with catheters inserted via blood vessels instead of open heart surgery. Typically, imaging devices such as echocardiography or fluoroscopy guide these operations. In comparison to surgery, the technique offers faster recovery, less time in the hospital, and fewer complications. To address congenital and acquired cardiac issues and improve the quality of life of young children, pediatric interventional cardiology is a must. Several key drivers are responsible for the significant growth of the Asia-Pacific pediatric interventional cardiology market. The demand for better pediatric cardiac care is fueled by the increasing prevalence of congenital heart diseases, particularly in populous countries such as China and India. Availability of minimally invasive interventions is being enhanced by improved healthcare infrastructure, increased government support, and increased investment in medical technology. In addition, the availability of skilled healthcare professionals, increased health insurance coverage, and improved parental awareness are all contributing to market growth. Adoption of pediatric interventional cardiology in the Asia-Pacific region is being led by advances in diagnostic equipment and interventional devices, which also facilitate enhanced outcomes. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to grow enormously because of the rise in the number of congenital heart abnormalities (CHDs). The rate of babies born with congenital heart defects has increased enormously because of the rise in birth rates in countries like China and India. Due to advances in diagnostic technologies such as newborn screening and fetal echocardiography, early identification has increased. As parents and physicians become increasingly aware, more children are being diagnosed early and referred for treatment. Open cardiac surgery is less required when these issues are treated with minimally invasive methods offered by pediatric interventional cardiology. Advanced pediatric cardiac interventions remain in high demand in the Asia-Pacific region because of the increasing incidence of congenital heart disease and greater access to specialist care. The Asia-Pacific Pediatric Interventional Cardiology Market is likely to grow tremendously with the enhanced healthcare infrastructure. In countries such as China, India, and Southeast Asia, economic growth and urbanization have led to massive investments in healthcare systems. Availability of quality interventional therapy to children with heart issues has been enhanced through the expansion of specialist cardiac centers, the presence of state-of-the-art medical technology, and improved training of pediatric cardiologists. Treatment outcomes and hospital capacities are being enhanced through international cooperation and public-private alliances. Demand is also being driven by the expansion of digital health platforms and telemedicine, which are bridging the gap between rural communities and specialist cardiac care. In Asia-Pacific, increasing numbers of children are enjoying early diagnosis and minimally invasive cardiac surgery as healthcare systems improve. Asia-Pacific Pediatric Interventional Cardiology Market is anticipated to grow enormously due to technological advances in minimally invasive technology. Pediatric cardiac therapy has been revolutionized by leaps in imaging modalities, catheter-based intervention, and downsized devices. Congenital heart disease now can be targeted exactly and effectively with no need for open-heart surgery due to these technologies that reduce hospital stay, accelerate recovery, and reduce risk of complications. The development of smaller, child-specific devices such as balloons, stents, and occluders has enhanced the safety and effectiveness of newborn and young children's treatments. With growing investments in healthcare innovation, countries in the Asia-Pacific region are adopting these advanced tools at a growing pace. Treatment options and market expansion are being significantly enhanced by the incorporation of technology in pediatric cardiology as it becomes increasingly accessible and affordable. One major obstacle facing the Asia-Pacific pediatric interventional cardiology market is the high cost of therapy. Many families, especially those in lower-income areas, cannot afford the high costs of advanced operations, specialist equipment, and hospital stays. Even though insurance coverage is growing, it frequently falls short of covering all expenses, particularly in developing nations. The overall development and efficacy of pediatric interventional cardiology in the area are hampered by this financial barrier, which restricts children with congenital heart abnormalities' access to prompt, life-saving therapies. The Asia-Pacific Pediatric Interventional Cardiology Market faces many challenges, one of which is limited access to specialized care. Advanced pediatric cardiac centers are few and far between, and healthcare infrastructure is sometimes inadequate in rural and isolated places. Timely identification and treatment of congenital cardiac abnormalities are hindered by this lack of access. Long commutes to receive care may be necessary for families in underprivileged areas, further postponing intervention. This discrepancy in access to healthcare poses serious obstacles to fair treatment throughout the area. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $829.09 Million Forecasted Market Value (USD) by 2033 $1.52 Billion Compound Annual Growth Rate 7% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Pediatric Interventional Cardiology Market5.1 Historical Market Trends5.2 Market Forecast6. Asia-Pacific Pediatric Interventional Cardiology Market Share Analysis6.1 By Device Type6.2 By Procedure6.3 By End Use6.4 By Countries7. Device Type7.1 Transcatheter Heart Valves7.2 Atherectomy Devices7.3 Catheters7.4 Closure Devices7.5 Balloons7.6 Stents7.7 Others8. Procedure8.1 Catheter-based Valve Implantation8.2 Congenital Haert Defect Correction8.3 Angioplasty8.4 Coronary Thrombectomy8.5 Others9. End Use9.1 Hospitals9.2 Ambulatory Surgical Centers9.3 Others10. Countries10.1 China10.2 Japan10.3 India10.4 South Korea10.5 Thailand10.6 Malaysia10.7 Indonesia10.8 Australia10.9 New Zealand10.10 Rest of Asia-Pacific11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Abbott Laboratories Inc.13.1.1 Overviews13.1.2 Key Person13.1.3 Recent Developments & Strategies13.1.4 Revenue Analysis13.2 Boston Scientific Corporation13.3 Medtronic PLC13.4 B. Braun13.5 Biosensors International Group, Ltd.13.6 Siemens AG13.7 Cardinal Health Inc.13.8 Terumo Medical CorporationFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Pollen Allergy Market Analysis Report 2025: Innovative Strategies in Pollen Allergy Diagnosis and Treatment Emerge - Global Forecast to 2030
This comprehensive report delivers insights into market trends, drivers, and forecasts, covering recent tariff developments affecting the industry. Pollen allergies, increasingly prevalent worldwide, are exacerbated by urbanization, climate change, and pollution. Advances in diagnosis and treatment, including molecular diagnostics and allergen immunotherapy, are shaping the market. With regions like Asia-Pacific driving growth due to healthcare investments, the report explores comprehensive market analysis, competitive landscapes, emerging trends, and regional dynamics, guiding strategic business decisions. Pollen Allergy Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to global market for Pollen Allergy was valued at US$5.4 Billion in 2024 and is projected to reach US$6.7 Billion by 2030, growing at a CAGR of 3.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pollen Allergy market. Global Pollen Allergy Market - Key Trends & Drivers SummarizedWhy Is Pollen Allergy Emerging as a Global Public Health Concern?Pollen allergy, medically referred to as seasonal allergic rhinitis or hay fever, is becoming a widespread public health issue affecting hundreds of millions globally. Characterized by symptoms such as nasal congestion, sneezing, watery eyes, and respiratory discomfort, the condition results from hypersensitivity of the immune system to pollen from grasses, weeds, and trees. The growing prevalence of pollen-induced allergies is closely linked to urbanization, climate change, increased air pollution, and extended pollen seasons - factors that together intensify allergen exposure and areas are reporting higher allergy rates due to the "urban heat island" effect and the proliferation of allergenic plant species in landscaping. Moreover, industrial emissions and diesel particulates interact with pollen grains, increasing their allergenicity and aggravating symptoms in sensitive populations. This trend is not limited to developed countries - rising diagnosis rates in Asia-Pacific, Latin America, and parts of Africa highlight that pollen allergy is fast becoming a global epidemic, particularly among children, adolescents, and working-age adults who suffer significant quality-of-life disruptions and productivity Are Diagnosis and Therapeutic Strategies Evolving for Effective Symptom Management?The diagnosis of pollen allergy traditionally involves skin prick tests, blood IgE assays, and clinical history analysis. However, recent developments in molecular diagnostics now enable allergen component-resolved diagnostics (CRD), which offer precise identification of the specific proteins within pollen that trigger hypersensitivity reactions. CRD is helping to tailor immunotherapy approaches and minimize cross-reactivity, especially in poly-sensitized individuals reacting to multiple environmental management includes antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and decongestants, with growing interest in combination therapies for multi-symptom control. Allergen immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT), remains the only long-term disease-modifying treatment. AIT desensitizes the immune system through controlled allergen exposure and is gaining popularity due to its potential to prevent the progression of allergic rhinitis to asthma. Over-the-counter (OTC) allergy remedies, air filtration devices, and mobile health apps for pollen forecasting are further supporting symptom avoidance and self-management among patients Is Innovation Taking Shape Across Diagnostics, Delivery Formats, and Regional Care Models?Innovation in the pollen allergy market is not confined to pharmaceuticals but spans across diagnostics, delivery systems, and digital therapeutics. Needle-free delivery devices for immunotherapy and metered-dose nasal sprays are enhancing patient adherence and reducing discomfort. Biotech firms are developing hypoallergenic recombinant pollen allergens and adjuvant-enhanced immunotherapy formulations for improved efficacy and reduced adverse reactions. These technologies are creating a shift toward personalized allergy care, especially in high-income enabled care models are also gaining ground. Wearable air quality sensors, smartphone apps integrated with pollen dispersion models, and teleconsultation services are empowering patients to anticipate triggers and access timely medical support. Regionally, Europe remains at the forefront in allergy research and treatment accessibility, while North America shows strong commercial uptake of OTC and immunotherapy products. Asia-Pacific is emerging as a high-potential market, driven by rising allergic disease awareness, urban air quality challenges, and increasing healthcare investments. Governments are initiating school and workplace screening programs to identify and manage allergy-prone populations more Driving the Accelerated Growth of the Global Pollen Allergy Market?The growth in the global pollen allergy market is driven by several factors, including the rising global incidence of allergic rhinitis, worsening air quality, and longer pollen seasons linked to climate change. Increasing environmental awareness, improved allergy diagnostics, and broader availability of OTC antihistamines and immunotherapy solutions are further contributing to market expansion. Healthcare systems are also recognizing the socioeconomic impact of allergic rhinitis, which leads to missed school days, absenteeism, and comorbidities like sinusitis and advancements in allergy testing, predictive modeling, and digital health management are enhancing early diagnosis and sustained care. Pharmaceutical innovations in non-sedating antihistamines, nasal corticosteroid combinations, and biologics are improving symptom control and reducing patient dropout from long-term treatment regimens. With growing emphasis on preventive healthcare, environmental control measures, and personalized immunotherapy, the pollen allergy market is expected to witness robust growth, especially as climate change continues to alter allergen distribution patterns and intensify the global allergic disease Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Aimmune Therapeutics, Alcon Inc., ALK-Abello A/S, Allergopharma and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$4.4 Billion by 2030 with a CAGR of a 4.2%. The Consumables segment is also set to grow at 3.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 7.0% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Instruments, Consumables, Services) Therapeutics Drug Class (Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, Immunotherapy) Allergen Type (Food, Inhaled, Drug, Other Allergen Types) End-Use (Diagnostic Laboratories, Hospitals, Other End-Uses) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 498 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.4 Billion Forecasted Market Value (USD) by 2030 $6.7 Billion Compound Annual Growth Rate 3.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Pollen Allergy - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Prevalence of Seasonal Allergic Rhinitis Spurs Growth in the Pollen Allergy Management Market Expansion of Urbanization and Air Pollution Throws the Spotlight on Heightened Allergen Sensitization Development of Non-Sedating Antihistamines and Long-Acting Therapies Enhances Daily Symptom Control Growth in Immunotherapy and SLIT (Sublingual Immunotherapy) Adoption Expands Treatment Landscape Innovation in Air Filtration, Pollen Barriers, and Nasal Sprays Drives Preventive Allergy Management Increasing Demand for OTC Remedies and Natural Allergy Relief Products Fuels Consumer Healthcare Sales Collaboration With ENT Specialists and Allergy Clinics Strengthens Integrated Treatment Approaches Surge in Home and Portable Air Quality Devices Propels Pollen Monitoring Integration Focus on Rapid Allergen Diagnostic Testing and Home Kits Enhances Consumer Empowerment Growth in Biologics and Monoclonal Antibody Therapy Expands Options for Severe Allergy Management Advances in Allergen Mapping and Pollen Forecasting Drive Personalized Treatment Solutions Expansion of Mobile Health and Allergy Management Apps Spurs Digital Health Adoption in Allergy Control Participation in Regulatory Guidelines for Allergy Medication Labeling Strengthens Safety Profiles Increasing Awareness of Cross-Reactivity and Food-Pollen Syndrome Drives Demand for Educational Resources Entry Into Pediatric Allergy Management Market Enhances Age-Specific Treatment Accessibility Rising Popularity of Nasal Filters, HEPA Masks, and Wearables Strengthens Non-Pharmacological Product Category Investment in Botanical and Non-Corticosteroid Therapeutics Enhances Natural Remedy Pipeline Expansion of Allergy Care in Emerging Markets Through E-Pharmacy and Telehealth Platforms Supports Access Differentiation Through Symptom Tracker Integration and Adherence Tools Improves Chronic Case Outcomes Global Climate Change Patterns Alter Pollen Seasons, Increasing Duration and Intensity of Allergic Episodes FOCUS ON SELECT PLAYERS AbbVie Inc. Aimmune Therapeutics Alcon Inc. ALK-Abello A/S Allergopharma Allergy Therapeutics ASIT Biotech SA Bayer AG Biomay AG bioMerieux SA Circassia Pharmaceuticals DBV Technologies Genentech Inc. GlaxoSmithKline plc HAL Allergy Group HOB Biotech Group Corp Ltd Johnson & Johnson LETIPharma Merck KGaA Stallergenes Greer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pollen Allergy Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Trump's tariff fallout? It's worse than we previously thought, says OECD
President Donald Trump's trade war will wreak greater economic damage than previously expected, both in the United States and everywhere else, according to new forecasts by the Organisation for Economic Co-operation and Development. In a report Tuesday, the group of 38 mostly wealthy nations sharply downgraded its 2025 economic growth forecast for America to 1.6% from the 2.2% projected in March and said growth would be even weaker next year. The report underscores the uncertainty and chaos around Trump's tariffs, as well as their potential to cause lasting harm across the world. The Paris-based organization cited higher tariffs, including retaliatory tariffs imposed on American exports, a slowdown in net immigration and a 'sizable reduction' in the federal workforce. The OECD also expects the global economy to slow markedly to 2.9% growth both this year and next — a downgrade from its prior forecasts of 3.1% and 3% respectively. That's based on the assumption that tariffs worldwide will remain at their mid-May levels, it said. 'The global economy has shifted from a period of resilient growth and declining inflation to a more uncertain path,' OECD Secretary-General Mathias Cormann said in a statement. 'Today's policy uncertainty is weakening trade and investment, diminishing consumer and business confidence and curbing growth prospects.' In its Economic Outlook report, the OECD said it expects the slowdown to be 'concentrated' in the US, Canada, Mexico and China — four of the countries most affected by Trump's new tariffs. Since retaking office in January, the US president has hiked import duties on most of America's trading partners and on key goods, including cars and steel. Despite his tariff plan hitting a legal stumbling block last week, a round of punishingly high 'reciprocal tariffs' are due to whack many of America's trading partners from July 9 unless they can strike a deal with Washington. The tariffs, their erratic implementation and the unpredictability that both have injected into the global economy are weighing on many businesses and consumers. According to the OECD, the new US import taxes, in combination with retaliatory trade barriers erected by China and Canada, are 'pointing to much greater disruption than during the US-China trade tensions in 2018-19' — a reference to the trade war during Trump's first term. The OECD said new levies risk pushing up inflation in the countries imposing them and that central banks — which hike interest rates to slow price rises — should 'remain vigilant.' In contrast, Trump has publicly pressured US Federal Reserve Chair Jerome Powell to cut the cost of borrowing in America, while Powell has preferred to wait to see how the president's tariffs will impact the world's largest economy before deciding whether to cut or raise rates. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
